Birgitta I. Hiddinga

Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function

Wendy Zondag, Lies M.A. Vingerhoets, Marc Durian et al. · Journal of Thrombosis and Haemostasis · 2013 · 84 citations

Medicine, Cardiology, Internal Medicine +11

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

Fenneke Zwierenga, Bianca van Veggel, Lizza Hendriks et al. · Lung Cancer · 2022 · 63 citations · Full text

Medicine, Oncology, Pharmacology +15

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Paul van der Leest, Birgitta I. Hiddinga, Anneke Miedema et al. · Molecular Oncology · 2021 · 52 citations · Full text

Medicine, Immunology, Oncology +17

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles

Bart Koopman, Anthonie J. van der Wekken, Arja ter Elst et al. · JCO Precision Oncology · 2020 · 48 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism

Wendy Zondag, Birgitta I. Hiddinga, Monique J. T. Crobach et al. · European Respiratory Journal · 2012 · 47 citations · Full text

Medicine, Clinical Sciences, Hematology +17